Please login to the form below

Not currently logged in
Email:
Password:

Alecensa

This page shows the latest Alecensa news and features for those working in and with pharma, biotech and healthcare.

NICE backs Roche’s Gazyvaro, Pfizer’s Lorviqua in new guidance

NICE backs Roche’s Gazyvaro, Pfizer’s Lorviqua in new guidance

first-line treatment with Alecensa (alectinib) or Zykadia (ceritinib, as well as Pfizer’s Xalkori (crizotinib) and at least one other ALK inhibitor. ... standard second-line treatment options after Alecensa and Zykadia – suggest Lorviqua can improve

Latest news

More from news
Approximately 16 fully matching, plus 23 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment
International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...

Infographics